$4995 | Single User
$9990 | Site License
$14985 | Enterprise License

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments
[Report Updated: 01-12-2016]

Published by GBI Research: 01 Dec 2016 | 43000 | In Stock

Introduction

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Summary

Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include both hereditary and sporadic conditions that are characterized by slow, irreversible, progressive dysfunction of the nervous system with the increasing degeneration of neurons, which causes symptoms such as motor impairment, memory loss and declining cognitive ability. Neurodegenerative disorders cannot currently be cured, and treatment is aimed at managing the disease indication in order to reduce the severity of symptoms and slow progression.

The report focuses on five key indications within neurodegenerative disorders: Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in amyotrophic lateral sclerosis and multiple sclerosis. This indicates the need for extensive R&D within this area.

Immunomodulators are the most effective and most common therapies used in neurodegenerative disorders. This class of compounds has been the most commercially successful in the past decade, particularly in the multiple sclerosis market, with many clinical trials underway for amyotrophic lateral sclerosis. The market for neurodegenerative disorders is largely accounted for by premium products, with generic products holding only a relatively small share. However, some generic products have been able to secure sizable market shares after the patent expiries of leading drugs. Glatopa (a generic version of Copaxone) recently entered the market and is expected to reach sales of 3m within the forecast period.

Although there is a high degree of failure and uncertainty within the R&D of neurodegenerative disorder drugs, the number of drugs in the pipeline is very high, at 1,494. The majority of pipeline products are novel active pharmaceutical ingredients, with only a small proportion of products being either generics or repositioned from other indications. This shows progression in terms of the variety of molecules being developed as therapeutic agents within the neurodegenerative disorders pipeline. The market is expected to grow over the forecast period, which is attributed to the approval of new drugs, as well as the increasing aging population.

Scope

- Global revenues for the neurodegenerative disorders market are forecast to grow at a compound annual growth rate of 7.42%, from .2 billion in 2015 to billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?

- The neurodegenerative disorders pipeline is large and diverse, and contains 1,494 products. How does the composition of the pipeline compare with that of the existing market?

- What mechanisms of action and molecule types are being trialed most commonly in pipeline products for the key indications?

- Which products will contribute most significantly to market growth, and which will achieve blockbuster status?

- Will the current market leaders retain their dominance over the forecast period, and how is their revenue share set to change?

Reasons to buy

This report will allow you to -

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis

- Visualize the composition of the neurodegenerative disorders market across each indication, in terms of dominant molecule types and targets, and key commercial assets and players

- Analyze the neurodegenerative disorders pipeline and stratify by stage of development, molecule type and molecular target, making use of a granular breakdown across key indications

- Understand the growth in patient epidemiology and market revenues for the neurodegenerative disorders market, globally and across the key players and product types

- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various neurodegenerative disorders

- Identify commercial opportunities in the neurodegenerative disorders deals landscape by analyzing trends in licensing and co-development deals

Table of Contents
for Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments [Report Updated: 01-12-2016]

  • 1 Table of Contents

    1 Table of Contents 5

    1.1 List of Tables 7

    1.2 List of Figures 7

    2 Introduction 10

    2.1 Therapy Area Introduction 10

    2.1.1 Alzheimer’s Disease 10

    2.1.2 Parkinson’s Disease 11

    2.1.3 Huntington’s Disease 11

    2.1.4 Amyotrophic Lateral Sclerosis 12

    2.1.5 Multiple Sclerosis 13

    2.2 Symptoms 14

    2.3 Etiology and Pathophysiology 15

    2.3.1 Pathophysiology 18

    2.4 Epidemiology Patterns: Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates 22

    2.4.1 Alzheimer’s Disease 23

    2.4.2 Parkinson’s Disease 24

    2.4.3 Huntington’s Disease 25

    2.4.4 Amyotrophic Lateral Sclerosis 26

    2.4.5 Multiple Sclerosis 27

    2.5 Co-morbidities and Complications 28

    2.6 Treatment 29

    2.6.1 Alzheimer’s Disease 29

    2.6.2 Parkinson’s Disease 30

    2.6.3 Huntington’s Disease 33

    2.6.4 Amyotrophic Lateral Sclerosis 33

    2.6.5 Multiple Sclerosis 33

    3 Key Marketed Products 35

    3.1 Overview 35

    3.2 Tecfidera (dimethyl fumarate) - Biogen 35

    3.3 Copaxone (glatiramer acetate) - Teva 37

    3.4 Tysabri (natalizumab) - Biogen 39

    3.5 Gilenya (fingolimod hydrochloride) - Novartis 41

    3.6 Avonex (interferon beta-1a) - Biogen 43

    3.7 Plegridy (peginterferon beta-1a) - Biogen 44

    3.8 Namenda/Memary/Ebixa/Axura/Namenda XR (memantine hydrochloride/memantine hydrochloride ER) - Merz Pharma/Lundbeck/Forest/Daiichi Sankyo 46

    3.9 Nuplazid (pimavanserin tartrate) - Acadia 48

    4 Pipeline Landscape Assessment 50

    4.1 Pipeline Development Landscape 50

    4.2 Molecular Targets in the Pipeline 53

    4.3 Clinical Trials 55

    4.3.1 Failure Rate 55

    4.3.2 Clinical Trial Duration 59

    4.3.3 Clinical Trial Size 63

    4.3.4 Aggregate Clinical Program Size 67

    4.4 Assessment of Key Pipeline Products 70

    4.4.1 Ocrelizumab - Roche 70

    4.4.2 Ozanimod - Celgene 72

    4.4.3 Solanezumab - Eli Lilly 73

    4.4.4 Crenezumab - Roche 74

    4.4.5 Tirasemtiv - Cytokinetics 76

    4.4.6 CVT-301 (Levodopa) - Acorda Therapeutics 78

    4.5 5.5 Conclusion 79

    5 Multi-scenario Market Forecast to 2022 80

    5.1 Overall Market Size 80

    5.2 Generic Penetration 82

    5.3 Revenue Forecast by Molecular Target 82

    5.3.1 Immunomodulators (interferon receptor/S1PR1/MHC II/IL-2 receptor/cells expressing B lymphocyte antigen CD20/glucocorticoid receptor) 83

    5.3.2 Neuromodulators (acetylcholinesterase/dopamine receptor/5HTA receptor) 83

    5.3.3 Amyloid Inhibitors (Amyloid Beta Inhibitors) 84

    5.3.4 APP inhibitors (BACE) 85

    6 Company Analysis and Positioning 86

    6.1 Revenue and Market Share Analysis by Company 87

    6.1.1 Biogen - Will the Patent Expiration of Tysabri Cause a Loss in Market Size? 92

    6.1.2 Novartis - Gradual Decline in Revenue due to Gilenya Patent Expiration 93

    6.1.3 Roche - Approval of Ocrelizumab to Drive Market Size 94

    6.1.4 Sanofi - Aubagio and Lemtrada to Become Blockbuster Drugs 95

    6.1.5 Teva - Gradual Decline in Revenue due to Patent Expiration of Products 96

    6.1.6 Acadia - Newly Approved Nuplazid Expected to Achieve Blockbuster Status in Forecast Period 97

    6.1.7 AbbVie - Pipeline Product Approval to Significantly Increase CAGR 98

    6.1.8 Eli Lilly - Solanezumab to Achieve Blockbuster Status following its Approval 99

    6.1.9 Celgene - Its First Product in Neurodegenerative Disorder Market to Reach Blockbuster Status in Forecast Period 100

    6.1.10 Lundbeck - Approval of Idalopirdine to Offset Loss in Revenue Caused by Patent Expiration of Azilect 101

    6.2 Company Landscape 102

    6.3 Marketed and Pipeline Portfolio Analysis 103

    7 Strategic Consolidations 105

    7.1 Licensing Deals 105

    7.1.1 Deals by Region, Year and Value 105

    7.1.2 Deals by Stage of Development and Value 107

    7.1.3 Deals by Molecule Type, Mechanism of Action and Value 108

    7.1.4 Table for Licensing Deals Valued above 0m 110

    7.2 Co-development Deals 113

    7.2.1 Deals by Region, Year and Value 113

    7.2.2 Deals by Stage of Development and Value 115

    7.2.3 Deals by Molecule Type, Mechanism of Action and Value 116

    7.2.4 Table for Co-development Deals Valued above 0m 118

    8 Appendix 120

    8.1 References 120

    8.2 Abbreviations 130

    8.3 Disease List 131

    8.4 Methodology 131

    8.4.1 Coverage 131

    8.4.2 Secondary Research 132

    8.4.3 Market Size and Revenue Forecasts 132

    8.4.4 Pipeline Analysis 132

    8.4.5 Competitive Landscape 133

    8.5 Contact Us 133

    8.6 Disclaimer 133

List Of Tables
in Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments [Report Updated: 01-12-2016]

1.1 List of Tables

Table 1: Neurodegenerative Disorders Therapeutics Market, Symptoms of AD, PD, HD, ALS and MS, 2016 14

Table 2: Neurodegenerative Disorders Therapeutics Market, Etiology of AD, PD, HD, ALS and MS, 2016 16

Table 3: Neurodegenerative Disorders , Global, Epidemiology of Neurodegenerative Disorders, 2016 23

Table 4: Neurodegenerative Disorders Therapeutics Market, Comorbidities Associated with AD, PD, HD, ALS and MS, 2016 29

Table 5: Neurodegenerative Disorders Therapeutics Market, Treatment Options Available for Parkinson’s Disease, 2016 31

Table 6: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tecfidera, 2016 36

Table 7: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Copaxone, 2016 38

Table 8: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Tysabri, 2016 40

Table 9: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Gilenya, 2016 41

Table 10: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Avonex, 2016 43

Table 11: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Plegridy, 2016 45

Table 12: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Namenda/Namenda XR, 2016 47

Table 13: Neurodegenerative Disorder Therapeutics Market, Global, Approved Indications for Nuplazid, 2016 48

Table 14: Neurodegenerative Disorders, Global, Annual Revenue for key Products ($bn), 2015-2022 81

Table 15: Neurodegenerative Disorders, Global, Revenue by Company, 2015-2022 88

Table 16: Neurodegenerative Disorders, Global, Licensing Deals Valued above 0m, 2006-2016 110

Table 17: Neurodegenerative Disorders, Global, Co-development Deals Valued above 0m, 2006-2016 118

List Of Figures, Charts and Diagrams
in Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments [Report Updated: 01-12-2016]

1.2 List of Figures

Figure 1: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Alzheimer’s Disease (‘000), 2015-2022 24

Figure 2: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Parkinson’s Disease (‘000), 2015-2022 25

Figure 3: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Huntington’s Disease (‘000), 2015-2022 26

Figure 4: Neurodegenerative Disorders, Seven Major Markets, Epidemiology Patterns for Amyotrophic Lateral Sclerosis (‘000), 2015-2022 27

Figure 5: Neurodegenerative disorders, Seven Major Markets, Epidemiology Patterns for Multiple Sclerosis (‘000), 2015-2022 28

Figure 6: Neurodegenerative Disorders, Global, Key Marketed Products and Approved Indications, 2016 35

Figure 7: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tecfidera ($bn), 2013-2022 37

Figure 8: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Copaxone ($bn), 2006-2022 39

Figure 9: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Tysabri ($bn), 2006-2022 41

Figure 10: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Gilenya ($bn), 2011-2022 43

Figure 11: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Avonex ($bn), 2006-2022 44

Figure 12: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Plegridy ($bn), 2014-2022 46

Figure 13: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Namenda/Namenda XR ($bn), 2006-2022 47

Figure 14: Neurodegenerative Disorder Therapeutics Market, Global, Annual Revenue for Nuplazid ($bn), 2016-2022 49

Figure 15: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Neurodegenerative Disorder by Stage of Development, Molecule Type and Program Type, 2016 51

Figure 16: Breakdown of Biologics in Neurodegenerative Disorders Pipeline, 2016 51

Figure 17: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Stage of Development, 2016 52

Figure 18: Neurodegenerative Disorders Therapeutics Market, Pipeline by Mechanism of Action (%), 2016 53

Figure 19: Neurodegenerative Disorders Therapeutics Market, Global, Pipeline for Key Neurodegenerative Disorder Indications by Mechanism of Action, 2016 54

Figure 20: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016 55

Figure 21: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016 56

Figure 22: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 57

Figure 23: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 58

Figure 24: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2016 59

Figure 25: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016 60

Figure 26: Neurodegenerative Disorders Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016 61

Figure 27: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016 62

Figure 28: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016 63

Figure 29: Neurodegenerative disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2015 64

Figure 30: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016 65

Figure 31: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016 66

Figure 32: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development (patients), 2006-2016 67

Figure 33: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016 68

Figure 34: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2015 69

Figure 35: Neurodegenerative Disorder Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016 70

Figure 36: Neurodegenerative Disorders, Global, Annual Revenue for Ocrelizumab ($bn), 2016-2022 71

Figure 37: Neurodegenerative Disorders, Global, Annual Revenue for Ozanimod ($bn), 2018-2022 73

Figure 38: Neurodegenerative Disorders, Global, Annual Revenue for Solanezumab ($bn), 2017-2022 74

Figure 39: Neurodegenerative Disorders, Global, Annual Revenue for Crenezumab ($m), 2017-2022 76

Figure 40: Neurodegenerative Disorders, Global, Annual Revenue for Tirasemtiv ($m), 2019-2022 77

Figure 41: Neurodegenerative Disorders, Global, Annual Revenue for CVT-301 ($m), 2018-2022 78

Figure 42: Neurodegenerative Disorder Therapeutics Market, Global, Market Size ($bn), 2015-2022 80

Figure 43: Neurodegenerative Disorders, Global, Annual Revenue for Key Products ($m), 2014-2022 82

Figure 44: Neurodegenerative Disorders, Global, Annual Revenue for Immunomodulators ($bn), 2015-2022 83

Figure 45: Neurodegenerative Disorders, Global, Annual Revenue for Neuromodulators ($bn), 2015-2022 84

Figure 46: Neurodegenerative Disorders, Global, Annual Revenue for Amyloid Inhibitors ($bn), 2015-2022 84

Figure 47: Neurodegenerative Disorders, Global, Annual Revenue for APP inhibitors ($m), 2015-2022 85

Figure 48: Neurodegenerative Disorders Therapeutics Market, Global, Cluster by Growth and Market Share, 2015-2022 86

Figure 49: Neurodegenerative Disorders, Global, Market Share by Company (%), 2015-2022 89

Figure 50: Neurodegenerative Disorders, Global, Companies by Compound Annual Growth Rate (%), 2014-2022 90

Figure 51: Neurodegenerative Disorders, Global, Revenue by Product Type, 2015-2022 91

Figure 52: Neurodegenerative Disorders, Global, Biogen Annual Revenue ($bn), 2015-2022 92

Figure 53: Neurodegenerative Disorders, Global, Novartis Annual Revenue ($bn), 2015-2022 93

Figure 54: Neurodegenerative Disorders, Global, Roche Annual Revenue ($bn), 2015-2022 94

Figure 55: Neurodegenerative Disorders, Global, Sanofi Annual Revenue ($bn), 2015-2022 95

Figure 56: Neurodegenerative Disorders, Global, Teva Annual Revenue ($bn), 2015-2022 96

Figure 57: Neurodegenerative Disorders, Global, Acadia Annual Revenue ($bn), 2015-2022 97

Figure 58: Neurodegenerative Disorders, Global, AbbVie Annual Revenue ($m), 2015-2022 98

Figure 59: Neurodegenerative Disorders, Global, Eli Lilly Annual Revenue ($m), 2015-2022 99

Figure 60: Neurodegenerative Disorders, Global, Celgene Annual Revenue ($m), 2015-2022 100

Figure 61: Neurodegenerative Disorders, Global, Lundbeck Annual Revenue ($m), 2015-2022 101

Figure 62: Neurodegenerative Disorders, Global, Companies by Type, 2016 102

Figure 63: Neurodegenerative Disorders, Global, High-Activity and Late-Stage Pipeline Developers by Level of Neurodegenerative Disorders, 2016 103

Figure 64: Neurodegenerative Disorders, Global, Proportion of Total Company Revenue Attributed to Neurodegenerative Disorders, 2015-2022 104

Figure 65: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016 106

Figure 66: Neurodegenerative Disorders, Global, Licensing Deals by Indication and Value, 2006-2016 107

Figure 67: Neurodegenerative Disorders, Global, Licensing Deals, 2006-2016 108

Figure 68: Neurodegenerative Disorders, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016 109

Figure 69: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016 114

Figure 70: Neurodegenerative Disorders, Global, Co-development Deals by Indication and Value, 2006-2016 115

Figure 71: Neurodegenerative Disorders, Global, Co-development Deals, 2006-2016 116

Figure 72: Neurodegenerative Disorders, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016 117

Additional Details

Publisher

GBI Research

Publisher Information

Reference

43000 |

Number of Pages

133

Report Format

PDF

GBI Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global CNS Therapeutics Market Size study, by Type (Neurodegenerative, Mood Disorders, Schizophrenia, Autism, Depression), by Application (Hospital Use, Clinic Use, Household, Others) and Regional Forecasts 2018-2025
Global CNS Therapeutics Market to reach USD 130 billion by 2025.Global CNS Therapeutics Market value...
01 Dec 2018 by Bizwit Research and Consulting USD $3,950 More Info
Global Exosomes Market Size Study By Workflow (Downstream Analysis, and Isolation Methods), By Biomolecule Type (mRNA, Non-Coding RNAs, DNA Fragments, Lipids, Proteins/Peptides), By Application (Infectious Diseases, Neurodegenerative Diseases, Cancer, and Cardiovascular Diseases) and By Regional Forecasts, 2018-2025
Global Exosomes Market to reach USD XXX million by 2025. Global Exosomes Market valued approximately...
22 Jul 2018 by Bizwit Research and Consulting USD $3,950 More Info
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrev...
07 Feb 2018 by GBI Research USD $4,995 More Info
Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD
Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominat...
01 Nov 2017 by GBI Research USD $6,995 More Info
Neurodegenerative Disorders Drug Development Pipeline Review, 2017
Neurodegenerative Disorders Drug Development Pipeline Review, 2017SummaryNeurodegenerative disorders...
21 Mar 2017 by GBI Research USD $3,995 More Info
Deutsches Zentrum fur Neurodegenerative Erkrankungen e V - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryDeutsches Zentrum fur Neurodegenerative Erkrankungen e V (DZNE) is a research institute that ...
19 Dec 2016 by Global Data USD $250 More Info
DNA Polymerase Market: By Application (Neurodegenerative diseases, Genetic disorders, Oncology & Others), By end user type (Bio-pharmaceutical Industry, Diagnostic centers, Forensic Industry) & By Region-Forecast (2016-2021)
The DNA polymerases are enzymes that are responsible for synthesis of DNA molecules from deoxy ribon...
17 Mar 2016 by USD $5,250 More Info
Neurodegenerative Disease Market: By Drug Class (NMDA, SSRIs, Dopamine Inhibitors) & by Indications (Parkinson’s & Huntington disease, Amyotrophic Lateral Sclerosis, Alzheimer’s disease) & Geography-Forecast (2016-2021)
Neurodegenerative disease or neurodegeneration is disease which is causes the progressive damage or ...
15 Jan 2016 by USD $5,250 More Info

This report is published by GBI Research

Download Free Report Summary PDF

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments [Report Updated: 01-12-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...